financetom
Business
financetom
/
Business
/
Will deliver FY22 EBITDA margin as promised; eyeing robust deal pipeline: Mindtree
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Will deliver FY22 EBITDA margin as promised; eyeing robust deal pipeline: Mindtree
Oct 14, 2021 6:29 AM

Mindtree CEO Debashis Chatterjee on Thursday said that the company is confident of delivering the EBITDA margin that it has promised for the financial year 2022.

“As far as EBITDA is concerned, there are enough controls, checks and balances that we have been putting in the system, which make us believe that it will be up. But at an overall fiscal level, we should be able to deliver the EBITDA as promised,” he said in an interview with CNBC-TV18.

Mindtree on Wednesday reported better-than-expected revenues and margins for the second quarter. The midcap IT firm reported a net profit of Rs 399 crore for the quarter ended September 30, up 16.2 percent QoQ. The revenue in dollar terms grew 12.8 percent sequentially to $350.1 million for Q2FY22 and 13.4 percent in constant currency terms.

The management also guided for industry-leading revenue growth in FY22.

"We want to continue on our journey of profitable growth and a double-digit growth this fiscal," Chatterjee said.

Throwing more light on the deal wins, he said the book is up almost 19 percent year on year. “We have an order book for $360 million. So from that perspective, we are very confident that the pipeline will convert into an order book as we go along... If you look at the strategy that we have adopted, we are focusing on a selected set of clients, doing a lot of upselling and cross-selling and that strategy is working out very well,” he stated.

Also Read

: Mindtree Q2 Earnings: Net profit up 16.2% QoQ at Rs 399 crore

“If you look at the top-line growth, it has been 12.8 percent year over year. So top-line clients continue to grow. But our focus is mining the next set of clients and I am really happy with the growth that we have which is almost a 19 percent quarter on quarter,” said Chatterjee.

Talking about attrition, he said it is an industry phenomenon and that the company is taking enough initiatives within the organisation from a talent engagement standpoint. “The kind of transformation work that we are doing would help people to be excited to be part of Mindtree. So there are a lot of other aspects of controlling attrition and managing talent engagement. We are doing innovative things in that area,” he said.

Also Read: IT upcycle has just begun; Mindtree, L&T Infotech to do much better, says Edelweiss Securities' Sandip Agarwal

Watch the accompanying video for the full interview

(Edited by : Niral Sharma)

First Published:Oct 14, 2021 3:29 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Blackstone to Take Japan's I'rom Private at 50% Premium
Update: Blackstone to Take Japan's I'rom Private at 50% Premium
May 13, 2024
09:32 AM EDT, 05/13/2024 (MT Newswires) -- (Updates with additional information) Blackstone (BX) said Monday its private equity funds and vehicles have entered a definitive agreement with the management of Japanese pharmaceutical services company I'rom Group to take it private. The asset management firm will offer to acquire I'rom shares at 2,800 yen ($17.96) per share -- about a 50%...
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program
May 13, 2024
09:31 AM EDT, 05/13/2024 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Monday that it has signed an accelerated share repurchase agreement with investment bank Jefferies to buy back $35 million of its common stock. Collegium said it will execute the deal as part of a $150 million share repurchase program the board authorized in January. Following the completion...
Update: GameStop Shares Surge After 'Roaring Kitty' Returns
Update: GameStop Shares Surge After 'Roaring Kitty' Returns
May 13, 2024
09:46 AM EDT, 05/13/2024 (MT Newswires) -- (Updates to add recent stock move in the headline and first paragraph.) GameStop ( GME ) shares were up more than 68% in recent Monday trading after Roaring Kitty, the social media persona that sparked a massive stock rally with the videogame retailer in 2021, returned online for the first time in three...
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders
May 13, 2024
09:34 AM EDT, 05/13/2024 (MT Newswires) -- AbbVie ( ABBV ) and Gilgamesh Pharmaceuticals said Monday that they have entered into an option-to-license agreement to develop neuroplastogens to treat psychiatric disorders. Development and commercialization activities will be led by AbbVie ( ABBV ) upon exercise of the option, according to the companies. Gilgamesh will get $65 million in upfront payment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved